Allovir Inc is a biotechnology company focused on developing innovative therapies to treat viral diseases and improve the outcomes for patients with life-threatening viral infections. The company was founded in 2013 as "ViraCyte" and later rebranded to Allovir in 2020 to reflect its broader therapeutic focus.
Allovir's primary goal is to develop T-cell therapies that harness the power of the immune system to target and eliminate viral infections. Their proprietary technology involves using cytomegalovirus (CMV)-specific T cells, which are engineered to recognize and attack virus-infected cells in patients with weakened immune systems, such as those who have undergone stem cell or organ transplantation.
Allovir's innovative approach to antiviral therapy has the potential to address critical unmet medical needs, particularly for patients with compromised immune systems who are at higher risk of severe viral infections. Their therapies are designed to improve patient outcomes and quality of life by preventing or treating viral diseases.
Allovir has been advancing its clinical programs and conducting research to demonstrate the safety and efficacy of its T-cell therapies. The company collaborates with various medical institutions and researchers to conduct clinical trials and gather data on the effectiveness of their treatments.